All the news Showing 10 of 217 articles from: Pharmaceutical industryGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources The Hepatitis Drug Market Is Worse Than Wall Street Realises Bloomberg / 04 October 2017 Is HCV Drug Development Nearing Its End? MedPage Today / 02 October 2017 Malaysia Issues Compulsory License for Gilead Hepatitis C Drug RAPS / 18 September 2017 J&J unit ends hepatitis C drug development in crowded market Reuters / 11 September 2017 Unitaid publishes Technology and Market Landscape for Hepatitis C Medicines Unitaid / 07 September 2017 AbbVie Mavyret Price Threatens Gilead Hepatitis Dominance Bloomberg / 07 August 2017 Reining in Drug Prices: Easier Said than Done MedPage Today / 02 August 2017 Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows Keith Alcorn / 27 July 2017 HIV, hepatitis B and C and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College, London, reported ... Regulus Discontinuing Development of RG-101 for HCV Regulus press release / 13 June 2017 Australian duo find global consumers for Indian generic drugs Economic Times / 23 May 2017 ← Prev1...45678...22Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Noticeboard Email bulletins News feeds